Fc receptor blockade by nipocalimab 15 mg/kg significantly improved clinical disease activity versus placebo and was safe and well tolerated in participants with moderate-to-severe, active Sjögren's d...

To determine the prognostic importance of worsening dyspnoea in systemic sclerosis (SSc) related interstitial lung disease (ILD).SSc patients were rec…

Purpose Interstitial pneumonia (IP) is associated with poor prognosis in lung cancer and increases the risk of acute exacerbation (AE). Few studies analyzed the relationship between fluorodeoxyglucose...

These findings support further evaluation of admilparant as a therapeutic option for patients with IPF or PPF in phase 3 trials.

BackgroundThe 2013 American Thoracic Society/European Respiratory Society Statement on the classification of the idiopathic interstitial pneumonias described 6 major and 2 rare subtypes of idiopathic interstitial pneumonia, as well as recognising unclassifiable disease.ObjectiveThe objective of this statement is to update the 2013 classification of interstitial pneumonia.MethodsFive co-chairs identified a committee of 32 experts in the field as well as two individuals with lived experience. Creation of the document was supported by a series of video meetings, first including the full committee and then subgroups assigned to draft specific sections of the document. The classification scheme was developed by consensus.ResultsThe multidisciplinary committee of experts identified four major advances to the classification of interstitial pneumonia: (1) expansion beyond idiopathic interstitial pneumonias to also include secondary causes; (2) identification of new subcategories and updated terms, including addition of bronchiolocentric interstitial pneumonia as a major pattern as well as changing from acute interstitial pneumonia to idiopathic diffuse alveolar damage and desquamative interstitial pneumonia to alveolar macrophage pneumonia; (3) subclassification of interstitial and alveolar filling disorders, with interstitial disorders further subclassified as fibrotic versus non-fibrotic; and (4) consideration of diagnostic confidence in patient evaluation and management. The committee also provided a comprehensive update on the status of potential molecular tools and identified future research priorities.ConclusionsThis update builds upon the previous classification approach by describing major advances in the classification of interstitial pneumonia over the last decade.

The association between calcium supplementation and the risk of incident idiopathic pulmonary fibrosis (IPF) is largely unknown.This study aimed to in…

In this study, the authors describe SANA, a nitroalkene derivative of salicylate, as a potential activator of creatine-dependent energy expenditure and thermogenesis in adipose tissue. Preclinical and...

הטיל האיראני שפגע השבוע במכון ויצמן למדע שברחובות גרם נזק כבד והותיר לא מעט לבבות שבורים של מיטב המוחות המדעיים בישראל. מתוך השבר הנורא נולדה מחויבות לשיקום המחקר. פרופ' אלדד צחור, חוקר מחלות לב: "המע...

<p>Dr. Mohleen Kang chats with Dr. Kerri Johannson and Dr. Tamera Corte about their article, "<a rel="nofollow"href="https://www.ats...

Prednisone is currently recommended as the first-line treatment for pulmonary sarcoidosis but is associated with many side effects. Methotrexate, which is recommended as a second-line treatment, ap...